ALTERITY THERAPEUTICS LTD(ATHE)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.2M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ATHE Stock Analysis & AI Quality Score
AI stock analysis and institutional research for ALTERITY THERAPEUTICS LTD (ATHE), a Healthcare sector company. ATHE is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.2m in revenue. Top institutional holders of ATHE by reported 13-F value include Twin Lakes Capital Management,, HB Wealth Management,, MORGAN STANLEY, based on the most recent SEC filings. ATHE trades on the Nasdaq exchange and files with the SEC under CIK 1131343. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ATHE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ALTERITY THERAPEUTICS LTD directly from SEC EDGAR.
AI Insight: ATHE Financial Trends
No financial data available across all periods; unable to construct meaningful trend analysis.
• All financial metrics (revenue, net income, operating income, operating cash flow, debt, equity) are missing across Q2 2020–Q2 2025.
⚠ Company appears to be pre-revenue or data is not yet public. Confirm filing status and disclosure timeline.
AI Insight: ATHE Ratio Trends
Insufficient financial data to assess trends; all profitability and return metrics are missing across the entire period.
• No operating margin, net profit margin, ROE, ROA, ROIC, or leverage data available for any quarter from Q2 2020 through Q2 2025.
⚠ Complete absence of reported financial metrics prevents trend analysis and risk assessment.
Get alerted when ATHE's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ALTERITY THERAPEUTICS LTD including:
Top Institutional Holders of ATHE
Twin Lakes Capital Management, LLC
$484.6K139,258 shHB Wealth Management, LLC
$203.4K58,460 shMORGAN STANLEY
$203.2K58,382 shGREENLEAF TRUST
$111.4K32,000 shCITADEL ADVISORS LLC
$71.5K20,077 shBNP PARIBAS FINANCIAL MARKETS
$23.7K6,809 shRHUMBLINE ADVISERS
$7.0K1,970 shGAMMA Investing LLC
$6.5K1,856 shOSAIC HOLDINGS, INC.
$240.0068 shRonald Blue Trust, Inc.
$139.0040 sh
| Fund | Value | Shares |
|---|---|---|
| Twin Lakes Capital Management, LLC | $484.6K | 139,258 |
| HB Wealth Management, LLC | $203.4K | 58,460 |
| MORGAN STANLEY | $203.2K | 58,382 |
| GREENLEAF TRUST | $111.4K | 32,000 |
| CITADEL ADVISORS LLC | $71.5K | 20,077 |
| BNP PARIBAS FINANCIAL MARKETS | $23.7K | 6,809 |
| RHUMBLINE ADVISERS | $7.0K | 1,970 |
| GAMMA Investing LLC | $6.5K | 1,856 |
| OSAIC HOLDINGS, INC. | $240.00 | 68 |
| Ronald Blue Trust, Inc. | $139.00 | 40 |
More Healthcare Companies
View all Healthcare →Put ATHE on your watchlist
Track score changes the day ALTERITY THERAPEUTICS LTD files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ATHE a good stock to buy?
13F Pro's AI-powered analysis of ALTERITY THERAPEUTICS LTD (ATHE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ATHE are available on the ATHE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ATHE?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ATHE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ALTERITY THERAPEUTICS LTD's investment landscape.